INOVIQ will restart its EXO-OC ovarian cancer program through a staged optimisation and verification process after an independent review found sample collection and handling were the main sources of variability. The company is targeting US laboratory-developed test readiness in the first half of 2028, while a leadership change adds another moving part.
- Independent review identifies pre-analytical sample variability as the primary study issue
- Four-stage EXO-OC pathway targets US LDT readiness in H1 2028
- A$7.650 million cash at quarter end, plus A$1.782 million post-period R&D refund
- Peter Gunzburg assumes interim Executive Chair role after CEO departure
- Quarterly operating cash use of A$1.688 million implies 4.5 quarters of funding at reported burn
EXO-OC Moves From Failed Study to Staged Rebuild
INOVIQ Limited (ASX:IIQ) is reshaping its lead ovarian cancer diagnostic program after the OC2200 study could not produce a meaningful assessment of EXO-OC performance. An independent review by US diagnostics specialist Dr Mathew Moore concluded that differences in pre-analytical sample collection and handling were the primary source of study variability, while recommending changes to tumour-specific extracellular-vesicle capture, biomarker selection and sample standardisation.
The finding does not establish clinical performance for the test. It does, however, give INOVIQ a defined route to continue development: optimise the assay, verify it in an independently collected cohort, transfer it to a US CAP/CLIA-certified laboratory and then pursue laboratory-developed test commercialisation if validation succeeds. The company is targeting LDT readiness in H1 CY2028, a later timetable than the earlier goal of reaching LDT-ready status by December 2026. The revised plan follows the EXO-OC sample setback, which had previously prompted a technical review and refined development approach.
Four Stages Put Clinical Verification Ahead of Commercialisation
Stage 1, already under way in the third quarter of 2026, focuses on improving EXO-NET capture of tumour-specific extracellular vesicles and refining EXO-OC’s biomarker panel. Stage 2 will test the revised assay in an independent cohort containing average- and high-risk women with ovarian cancer, using a standardised collection protocol.
Only after those steps does INOVIQ plan to begin US technology transfer and laboratory validation. The prospective laboratory partner would lead commercial launch, pricing and reimbursement activities if the test ultimately reaches the LDT market. That sequence makes the next meaningful milestones technical rather than commercial: the optimisation work, the design of the independent cohort and the appointment of a suitable US laboratory partner.
CAR-Exosome Program Remains Preclinical
INOVIQ is continuing to spread its development effort across diagnostics and therapeutics. Its CAR-exosome platform produced positive in-vitro results in ovarian cancer cell lines, with CA125-targeting constructs achieving more than 90% tumour-cell killing in two models within 48 hours and about 50% in the aggressive SK-OV-3 model. EGFR-targeting constructs achieved more than 80% killing in the first two models. Those results are laboratory proof-of-concept findings, not evidence of clinical efficacy, and the program remains in preclinical and manufacturing development. New in-vitro data for dual-action CAR-exosomes in triple-negative breast cancer is expected in the fourth quarter of 2026, building on the earlier CAR-exosome proof-of-concept.
Cash Supports the Reset as Leadership Changes
INOVIQ held A$7.650 million in cash at 30 September, after using A$1.688 million in operating activities during the quarter. On the company’s reported calculation, that cash and an unused A$20,000 facility represented 4.5 quarters of funding at the quarter’s operating cash-use rate. A further A$1.782 million R&D Tax Incentive refund arrived after quarter end, giving the balance sheet additional support, although the filing does not recast the runway calculation around that receipt.
The quarter also brought a corporate transition. Dr Leearne Hinch departed as CEO on 27 October after agreeing with the board to step down, with Chairman Peter Gunzburg taking over as interim Executive Chair without additional remuneration while an executive search proceeds. The immediate test for the new leadership arrangement is whether INOVIQ can keep the EXO-OC reset disciplined enough to reach independent verification without allowing its parallel CAR-exosome ambitions to dilute the capital focus the company says it is pursuing.
Bottom Line?
The next valuation-relevant evidence is unlikely to come from the 2028 target itself, but from whether assay optimisation and standardised clinical verification can repair confidence in EXO-OC.
Questions in the middle?
- Can INOVIQ complete assay optimisation and define an independent cohort that avoids the sample variability that undermined OC2200?
- When will the company secure a US CAP/CLIA-certified laboratory partner, and what validation work will that partnership require?
- Will the interim leadership period affect the pace or funding of EXO-OC and CAR-exosome development?